Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis

Yunqian Li(Jilin University), Zefang Ren(Sun Yat-sen University), Zhuozhi Liang(Sun Yat-sen University), Ying Lin(Sun Yat-sen University), Qiang Liu(China Agricultural University), XingLi Gan(Sun Yat-sen University), Hengming Ye(Guangdong Medical College), Lu‐Ying Tang(Sun Yat-sen University), Xiaoming Xie(Sun Yat-sen University Cancer Center)

BMC Women s Health

May 8, 2023

10.1186/s12905-023-02383-3

Cited by 1

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

|Annals of Oncology|2021|724

Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week

|Nature Communications|2021|261

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment

|JAMA|2020|229

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

|Nature Communications|2022|214